The company is a developer and manufacturer of probiotics and vitamin K2-7
Novozymes has acquired a majority stake in Synergia Life Sciences, a developer of spore probiotics and vitamin K2-7, for DKK 1bn ($150m), a move aimed to strengthen its human health business and accelerate its functional food offering.
The acquired company has a global footprint, with three production sites in India, and its vitamin K2-7 portfolio is planned to support the growth of Novozymes’ biohealth platform.
“I am very pleased to announce Novozymes’ acquisition of Synergia Life Sciences. The company’s proven portfolio and strong production capacity for spore probiotics and vitamin K2-7 strengthens our human health business and accelerates our functional food offerings. Synergia Life Sciences is highly synergistic to our BioHealth-business and the previous acquisitions of PrecisionBiotics Group and Microbiome Labs. The complementary strategic fit between Synergia Life Sciences and our existing activities in BioHealth and Novozymes in general ensures a strong foundation for future growth in attractive high-growth markets. In short – we are executing on our strategy,” said Ester Baiget, President and CEO of Novozymes.
This is the company's third human health-related acquisition since mid-2020.
Synergia is a key supplier to Microbiome Labs, which was acquired by Novozymes in early 2021. Its founders will continue to be actively involved in the business.
"Novozymes’ strong presence in the functional foods and dietary supplement space makes this a strategic fit for Synergia’s innovative product portfolio. We are very excited to be part of the Novozymes family," said Dilip Mehta, CEO of Synergia Life Sciences.